Format

Send to

Choose Destination
Enferm Infecc Microbiol Clin. 2014 Mar;32 Suppl 2:32-7. doi: 10.1016/S0213-005X(14)70156-9.

[Potential utility of ceftaroline fosamil in osteoarticular infections].

[Article in Spanish]

Author information

1
Servicio de Enfermedades Infecciosas, Hospital Ramón y Cajal, IRYCIS, Madrid, España. Electronic address: javier.cobo@salud.madrid.org.
2
Servicio de Enfermedades Infecciosas, Hospital Universitario de Bellvitge, IDIBELL, L'Hospitalet de Llobregat, Barcelona, España.

Abstract

Osteoarticular infections (OAI) include a wide-usually complex-spectrum of clinical scenarios. The approach is usually medical-surgical. In addition to this complexity, there is a low grade of evidence in the medical literature on these infections. Nevertheless, it is possible-and necessary-to integrate microbiological, pharmacological, experimental and clinical information to achieve the best possible clinical results. The most appropriate choice of antibiotic therapy largely depends on the clinical scenario and, obviously, on the microorganisms involved. Given the protagonism of staphylococci in OAI, it is appropriate to elucidate the role that could be played by a new antistaphylococcic agent in these infections. For clinicians who manage OAI, the incorporation of ceftaroline represents the recovery of a beta-lactam to treat methicillin-resistant staphylococci. This perspective can be used to guide the potential role of this new antibiotic for the management of OAI in various scenarios and the clinical research required for its introduction in clinical practice.

KEYWORDS:

Arthritis; Artritis; Ceftarolina; Ceftaroline; Infección de prótesis articulares; Osteomielitis; Osteomyelitis; Prosthetic joint infection

PMID:
24702977
DOI:
10.1016/S0213-005X(14)70156-9
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center